問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

China Medical University Hospital

List

1712Cases

2007-12-01 - 2012-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2008-10-01 - 2012-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated1Sites

Suspended1Sites

2010-02-01 - 2012-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2012-09-01 - 2018-01-04

Phase III

Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination with Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen

  • Condition/Disease

    Metastatic Castration Resistant Prostate Cancer

  • Test Drug

    XRP6258

Participate Sites
3Sites

Terminated2Sites

Study ended1Sites

2011-09-29 - 2013-12-16

Phase II

A Phase 1-2 trial of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    MM-121(SAR256212)

Participate Sites
6Sites

Terminated6Sites

2009-11-01 - 2017-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2010-09-30 - 2012-08-31

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2021-01-30 - 2022-03-31

Phase II

A phase II,Placebo-controlled, Randomized, Observer-blind Study to Evaluate the Immunogenicity, Safety and Tolerability of UB-612 Vaccine against COVID-19 in Adolescent, Younger and Elderly Adult Volunteers

  • Condition/Disease

    COVID-19

  • Test Drug

    UB-612

Participate Sites
12Sites

Recruiting1Sites

Terminated11Sites

2021-07-15 - 2021-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2020-09-01 - 2021-05-31

Phase I

A phase I, open-label study to evaluate the safety, tolerability, and immunogenicity of UB-612 vaccine in healthy adult volunteers

  • Condition/Disease

    Prevent COVID-19 infection

  • Test Drug

    UB-612

Participate Sites
1Sites

Study ended1Sites

黃高彬
China Medical University Hospital

Division of Infectious Disease

1 96 97 98 99 100 172
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB